| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Capecitabine as adjuvant treatment for stage III colon cancer.
|
N Engl J Med
|
2005
|
6.22
|
|
2
|
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
|
Lancet
|
2005
|
5.01
|
|
3
|
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.
|
Nat Genet
|
2010
|
3.93
|
|
4
|
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study.
|
Lancet Oncol
|
2008
|
3.60
|
|
5
|
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
|
J Clin Oncol
|
2007
|
3.33
|
|
6
|
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
|
Nat Genet
|
2013
|
2.44
|
|
7
|
Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer.
|
Cancer Res
|
2013
|
1.99
|
|
8
|
Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome.
|
Am J Hum Genet
|
2010
|
1.97
|
|
9
|
Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
1.84
|
|
10
|
Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
|
J Clin Oncol
|
2006
|
1.83
|
|
11
|
Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain.
|
Environ Health Perspect
|
2010
|
1.81
|
|
12
|
Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools.
|
Am J Epidemiol
|
2006
|
1.73
|
|
13
|
Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk.
|
PLoS Genet
|
2007
|
1.68
|
|
14
|
Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study.
|
Clin Cancer Res
|
2007
|
1.68
|
|
15
|
Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines.
|
Mol Cancer Ther
|
2005
|
1.63
|
|
16
|
Total fluid and water consumption and the joint effect of exposure to disinfection by-products on risk of bladder cancer.
|
Environ Health Perspect
|
2007
|
1.60
|
|
17
|
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.
|
Eur J Cancer
|
2007
|
1.58
|
|
18
|
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
|
Cancer Res
|
2006
|
1.57
|
|
19
|
Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.52
|
|
20
|
Determinants of quality of interview and impact on risk estimates in a case-control study of bladder cancer.
|
Am J Epidemiol
|
2009
|
1.49
|
|
21
|
Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage.
|
Clin Transl Oncol
|
2005
|
1.44
|
|
22
|
Genetic variation in the nucleotide excision repair pathway and bladder cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
1.43
|
|
23
|
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3.
|
Hum Mol Genet
|
2011
|
1.36
|
|
24
|
Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk.
|
Proc Natl Acad Sci U S A
|
2012
|
1.36
|
|
25
|
Genome-wide association study identifies multiple loci associated with bladder cancer risk.
|
Hum Mol Genet
|
2013
|
1.34
|
|
26
|
Genetic variation in the base excision repair pathway and bladder cancer risk.
|
Hum Genet
|
2007
|
1.33
|
|
27
|
Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer.
|
Hum Mol Genet
|
2012
|
1.31
|
|
28
|
Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk.
|
Carcinogenesis
|
2007
|
1.21
|
|
29
|
Genetic susceptibility to distinct bladder cancer subphenotypes.
|
Eur Urol
|
2009
|
1.19
|
|
30
|
Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer.
|
Int J Cancer
|
2007
|
1.16
|
|
31
|
Food, nutrient and heterocyclic amine intake and the risk of bladder cancer.
|
Eur J Cancer
|
2007
|
1.15
|
|
32
|
Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: the Spanish bladder cancer study.
|
Int J Cancer
|
2013
|
1.14
|
|
33
|
Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study.
|
Int J Epidemiol
|
2007
|
1.12
|
|
34
|
Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes.
|
Carcinogenesis
|
2008
|
1.11
|
|
35
|
TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis.
|
Int J Cancer
|
2009
|
1.11
|
|
36
|
Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
1.08
|
|
37
|
Pancreatic cancer risk and levels of trace elements.
|
Gut
|
2011
|
1.06
|
|
38
|
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
|
J Clin Oncol
|
2005
|
1.06
|
|
39
|
Genetic and non-genetic predictors of LINE-1 methylation in leukocyte DNA.
|
Environ Health Perspect
|
2013
|
1.02
|
|
40
|
Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background.
|
PLoS One
|
2012
|
1.00
|
|
41
|
Does increased urination frequency protect against bladder cancer?
|
Int J Cancer
|
2008
|
0.98
|
|
42
|
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.95
|
|
43
|
Air pollution and risk of urinary bladder cancer in a case-control study in Spain.
|
Occup Environ Med
|
2007
|
0.95
|
|
44
|
FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
|
Clin Cancer Res
|
2005
|
0.94
|
|
45
|
Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain.
|
Eur J Cancer
|
2006
|
0.93
|
|
46
|
Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study.
|
J Natl Cancer Inst
|
2012
|
0.91
|
|
47
|
The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study.
|
BMC Cancer
|
2009
|
0.91
|
|
48
|
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
|
Crit Rev Oncol Hematol
|
2008
|
0.90
|
|
49
|
Bladder cancer and reproductive factors among women in Spain.
|
Cancer Causes Control
|
2009
|
0.89
|
|
50
|
Utility of p16 immunohistochemistry for the identification of Lynch syndrome.
|
Clin Cancer Res
|
2009
|
0.87
|
|
51
|
The p53 pathway and outcome among patients with T1G3 bladder tumors.
|
Clin Cancer Res
|
2006
|
0.87
|
|
52
|
Food and nutrient intakes and K-ras mutations in exocrine pancreatic cancer.
|
J Epidemiol Community Health
|
2007
|
0.86
|
|
53
|
Urinary pH, cigarette smoking and bladder cancer risk.
|
Carcinogenesis
|
2011
|
0.86
|
|
54
|
Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines.
|
Mol Cancer Res
|
2007
|
0.86
|
|
55
|
Adjuvant chemotherapy for stages II, III and IV of colon cancer.
|
Clin Transl Oncol
|
2009
|
0.86
|
|
56
|
Biomarkers for early diagnosis of pancreatic cancer.
|
Expert Rev Gastroenterol Hepatol
|
2014
|
0.86
|
|
57
|
Treatment recommendations for metastatic colorectal cancer.
|
Clin Transl Oncol
|
2011
|
0.85
|
|
58
|
Coffee consumption, genetic susceptibility and bladder cancer risk.
|
Cancer Causes Control
|
2008
|
0.85
|
|
59
|
Unusual focal keratin expression in plexiform angiomyxoid myofibroblastic tumor: A case report and review of the literature.
|
Medicine (Baltimore)
|
2016
|
0.85
|
|
60
|
The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study.
|
BMC Cancer
|
2009
|
0.84
|
|
61
|
Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level.
|
Cancer Lett
|
2009
|
0.84
|
|
62
|
Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study.
|
Clin Transl Oncol
|
2010
|
0.84
|
|
63
|
Occupational exposures and risk of pancreatic cancer.
|
Eur J Epidemiol
|
2010
|
0.82
|
|
64
|
Micronuclei assessment in the urothelial cells of women using hair dyes and its modulation by genetic polymorphisms.
|
Cancer Lett
|
2008
|
0.82
|
|
65
|
Bulky DNA adduct formation and risk of bladder cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.82
|
|
66
|
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
|
J Gastrointest Cancer
|
2015
|
0.81
|
|
67
|
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
|
Eur J Cancer
|
2008
|
0.81
|
|
68
|
LINE-1 methylation in granulocyte DNA and trihalomethane exposure is associated with bladder cancer risk.
|
Epigenetics
|
2014
|
0.81
|
|
69
|
Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients.
|
Eur J Epidemiol
|
2011
|
0.81
|
|
70
|
Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer.
|
Lung Cancer
|
2008
|
0.81
|
|
71
|
Biological and statistical approaches for modeling exposure to specific trihalomethanes and bladder cancer risk.
|
Am J Epidemiol
|
2013
|
0.81
|
|
72
|
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
|
Cancer Metastasis Rev
|
2011
|
0.80
|
|
73
|
Whole genome prediction of bladder cancer risk with the Bayesian LASSO.
|
Genet Epidemiol
|
2014
|
0.80
|
|
74
|
Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer.
|
Int J Cancer
|
2003
|
0.80
|
|
75
|
Socioeconomic status and exposure to disinfection by-products in drinking water in Spain.
|
Environ Health
|
2011
|
0.80
|
|
76
|
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
|
Clin Colorectal Cancer
|
2012
|
0.79
|
|
77
|
Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer.
|
Carcinogenesis
|
2002
|
0.79
|
|
78
|
Lifetime history of alcohol consumption and K-ras mutations in pancreatic ductal adenocarcinoma.
|
Environ Mol Mutagen
|
2009
|
0.78
|
|
79
|
Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer.
|
Clin Lung Cancer
|
2004
|
0.78
|
|
80
|
Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.
|
Anticancer Drugs
|
2011
|
0.78
|
|
81
|
Lifetime history of tobacco consumption and K-ras mutations in exocrine pancreatic cancer.
|
Pancreas
|
2007
|
0.78
|
|
82
|
Past medical conditions and K-ras mutations in pancreatic ductal adenocarcinoma: a hypothesis-generating study.
|
Cancer Causes Control
|
2008
|
0.78
|
|
83
|
[Use of analgesics and aspirin in a Spanish multicenter study].
|
Gac Sanit
|
2005
|
0.77
|
|
84
|
Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs).
|
Clin Transl Oncol
|
2010
|
0.77
|
|
85
|
Follow-up recommendations and risk-reduction initiatives for Lynch syndrome.
|
Expert Rev Anticancer Ther
|
2012
|
0.77
|
|
86
|
New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies.
|
Expert Rev Anticancer Ther
|
2012
|
0.77
|
|
87
|
Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
|
Clin Transl Oncol
|
2011
|
0.77
|
|
88
|
Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis.
|
PLoS One
|
2012
|
0.76
|
|
89
|
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
|
Cancer Chemother Pharmacol
|
2010
|
0.76
|
|
90
|
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
|
Anticancer Drugs
|
2004
|
0.76
|
|
91
|
Accomplishments in 2007 in the treatment of advanced colorectal cancer.
|
Gastrointest Cancer Res
|
2008
|
0.76
|
|
92
|
Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor.
|
Anticancer Drugs
|
2011
|
0.76
|
|
93
|
Porocarcinoma: clinical evolution.
|
Dermatol Surg
|
2010
|
0.76
|
|
94
|
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
|
Acta Oncol
|
2008
|
0.75
|
|
95
|
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
|
Arch Pathol Lab Med
|
2016
|
0.75
|
|
96
|
UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.
|
Anticancer Drugs
|
2006
|
0.75
|
|
97
|
A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
|
Eur J Cancer
|
2013
|
0.75
|
|
98
|
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
|
Clin Transl Oncol
|
2011
|
0.75
|
|
99
|
Panhypopituitarism as first manifestation of a lung cancer.
|
Clin Transl Oncol
|
2007
|
0.75
|
|
100
|
Recommendations on current approach to gastric cancer.
|
Clin Transl Oncol
|
2009
|
0.75
|
|
101
|
Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis.
|
Clin Transl Oncol
|
2008
|
0.75
|
|
102
|
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
|
Clin Colorectal Cancer
|
2005
|
0.75
|
|
103
|
Biallelic MYH germline mutations as cause of Muir-Torre syndrome.
|
Fam Cancer
|
2010
|
0.75
|